JP2010523507A - ゲニステインの新規使用 - Google Patents
ゲニステインの新規使用 Download PDFInfo
- Publication number
- JP2010523507A JP2010523507A JP2010501418A JP2010501418A JP2010523507A JP 2010523507 A JP2010523507 A JP 2010523507A JP 2010501418 A JP2010501418 A JP 2010501418A JP 2010501418 A JP2010501418 A JP 2010501418A JP 2010523507 A JP2010523507 A JP 2010523507A
- Authority
- JP
- Japan
- Prior art keywords
- genistein
- composition
- dry eye
- food
- lkc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fodder In General (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
オバレクトマイズド(Ovarectomized)(OVX)雌性スプラーグドーリーラット(120〜160g)は人間の更年期状態のモデルであり(フリュークフェルダー・S・Cら、ドライアイと眼表面障害、マーセルデッカー、ニューヨーク、2004年)、したがって、自然発生したドライアイ眼表面(dry eye surface)疾患のモデルの役割を果たす。さらに、ホルモン補充の効果をゲニステインを用いた処理と比較するために、OVX動物の皮下をエストラジオールで処理してもよい。
ドライアイのモデルとして他に広く認められているのは、スコポラミンの皮下注射(10ml中5mg)または皮膚パッチまたはゲル投与を用いることによって、自然な涙液を産生させる副交感神経を遮断することによりラットにドライアイ状態を誘発させるスコポラミンモデルである(ダーソン(Durson)ら、Invest.Ophthalmol.Vis.Sci.、第43巻、pp.632〜8、2002年)。
0−CON、0−SCOP:対照動物各8匹(スコポラミンなしまたはスコポラミンあり)
50−SCOP:ゲニステイン50ppmを補充した動物8匹(スコポラミンあり)
250−SCOP:ゲニステイン250ppmを補充した動物8匹(スコポラミンあり)
中間検査=補充期間2.5週間
最終検査=補充期間5.0週間
ここからわかるように、スコポラミン処理されたラットにゲニステインを補充すると涙液量がほぼ対照値付近まで回復し、250mgを補充した群は50mgの群よりもこの傾向がより顕著であり、用量反応相関が存在する可能性を示唆している。
Claims (12)
- 人間および動物のドライアイ症候群またはLKCの治療および予防に有用な組成物を製造するためのゲニステインの使用。
- 前記組成物が、全身、好ましくは経口または局所投与用である、請求項1に記載の使用。
- ドライアイ症候群またはLKCの治療および予防におけるゲニステインの使用であって、それを有効量含む組成物を、その必要に応じて人間または動物に投与することを特徴とする、使用。
- 前記組成物が、全身的、好ましくは経口的に投与される、請求項3に記載の使用。
- 有効量のゲニステインを含む組成物を、その必要に応じて人間または動物に投与することによる、ドライアイ症候群またはLKCの治療および予防方法。
- 前記組成物が、全身的、好ましくは経口的に投与される、請求項5に記載の方法。
- ドライアイ症候群またはLKCの治療および予防に使用するための組成物であって、有効量のゲニステインを含むことを特徴とする、組成物。
- 全身、好ましくは経口投与用の、請求項7に記載の組成物。
- 医薬品剤形である、請求項7または請求項8に記載の組成物。
- 食品もしくは飼料または対応する栄養補助剤である、請求項7または請求項8に記載の組成物。
- ゲニステインまたはそれを含む組成物を補充した食品または飼料。
- 機能性食品または飲料である、請求項11に記載の食品または飼料。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07006833 | 2007-04-02 | ||
EP07006833.3 | 2007-04-02 | ||
PCT/EP2008/002563 WO2008119544A1 (en) | 2007-04-02 | 2008-04-01 | Novel use of genistein |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010523507A true JP2010523507A (ja) | 2010-07-15 |
JP5327816B2 JP5327816B2 (ja) | 2013-10-30 |
Family
ID=39619083
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010501418A Expired - Fee Related JP5327816B2 (ja) | 2007-04-02 | 2008-04-01 | ゲニステインの新規使用 |
Country Status (8)
Country | Link |
---|---|
US (2) | US20100120904A1 (ja) |
EP (1) | EP2129373B1 (ja) |
JP (1) | JP5327816B2 (ja) |
KR (1) | KR101472609B1 (ja) |
CN (1) | CN101652135B (ja) |
ES (1) | ES2423484T3 (ja) |
PL (1) | PL2129373T3 (ja) |
WO (1) | WO2008119544A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013510095A (ja) * | 2009-11-06 | 2013-03-21 | アルコン リサーチ, リミテッド | ドライアイの軽減のための栄養サプリメント |
WO2016081035A1 (en) * | 2014-11-21 | 2016-05-26 | Schoenwetter Phillip E | Novel antioxidant formulations |
WO2022018605A1 (en) * | 2020-07-19 | 2022-01-27 | Narayana Nethralaya Foundation | A formulation of combination of genistein and calcitriol for management of inflammatory ocular surface conditions |
EP4338798A1 (en) | 2022-09-16 | 2024-03-20 | Wasilewicz, Robert Henryk | Pharmaceutical preparation containing genistein for use in the prevention or treatment of glaucoma and/or ocular hypertension |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5041434A (en) * | 1991-08-17 | 1991-08-20 | Virginia Lubkin | Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application |
JP2001252045A (ja) * | 2000-03-13 | 2001-09-18 | Nicchu Igaku Kenkyusho:Kk | 発酵大豆から抽出した、ゲニスチインを主要原料とする抗ダイオキシン健康食品。 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7718694B2 (en) * | 1997-10-16 | 2010-05-18 | Children's Hospital & Research Center At Oakland | Compositions and methods for therapy for diseases characterized by defective chloride transport |
US6001368A (en) * | 1998-09-03 | 1999-12-14 | Protein Technologies International, Inc. | Method for inhibiting or reducing the risk of macular degeneration |
DE10026245A1 (de) * | 2000-05-26 | 2002-01-24 | Bayerische Motoren Werke Ag | Verfahren zum Datenaustausch zwischen mehreren Teilnehmern |
CN1352896A (zh) * | 2000-11-08 | 2002-06-12 | 程锦雁 | 从发酵大豆里提取genistein为抗癌和抗二恶英致癌的物质 |
KR100380865B1 (ko) * | 2000-12-06 | 2003-04-18 | 한국 한의학 연구원 | 골다공증 예방 및 치료에 효과를 갖는 괴화 추출물 |
EP1852115A1 (en) * | 2001-03-15 | 2007-11-07 | DSM IP Assets B.V. | Composition for the prevention of osteoporosis comprising a combination of isoflavones and polyunsaturated fatty acids |
ATE312605T1 (de) * | 2002-06-29 | 2005-12-15 | Aquanova Ger Solubilisate Tech | Isoflavonkonzentrate sowie verfahren zu ihrer herstellung |
-
2008
- 2008-04-01 KR KR1020097022783A patent/KR101472609B1/ko active IP Right Grant
- 2008-04-01 JP JP2010501418A patent/JP5327816B2/ja not_active Expired - Fee Related
- 2008-04-01 EP EP08716727.6A patent/EP2129373B1/en active Active
- 2008-04-01 ES ES08716727T patent/ES2423484T3/es active Active
- 2008-04-01 PL PL08716727T patent/PL2129373T3/pl unknown
- 2008-04-01 WO PCT/EP2008/002563 patent/WO2008119544A1/en active Application Filing
- 2008-04-01 US US12/594,284 patent/US20100120904A1/en not_active Abandoned
- 2008-04-01 CN CN2008800114791A patent/CN101652135B/zh not_active Expired - Fee Related
-
2018
- 2018-01-08 US US15/864,974 patent/US10471041B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5041434A (en) * | 1991-08-17 | 1991-08-20 | Virginia Lubkin | Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application |
JP2001252045A (ja) * | 2000-03-13 | 2001-09-18 | Nicchu Igaku Kenkyusho:Kk | 発酵大豆から抽出した、ゲニスチインを主要原料とする抗ダイオキシン健康食品。 |
Non-Patent Citations (3)
Title |
---|
JPN5010006339; AKRAMIAN J: ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY V438, 1998, P1005-1009 * |
JPN6013004836; Medical Hypotheses vol.66, 2006, p.1093-1114 * |
JPN7013000385; Environ Health Perspect vol.112, no.11, 2004, p.1137-42 * |
Also Published As
Publication number | Publication date |
---|---|
EP2129373A1 (en) | 2009-12-09 |
US20180133193A1 (en) | 2018-05-17 |
CN101652135A (zh) | 2010-02-17 |
EP2129373B1 (en) | 2013-05-22 |
US10471041B2 (en) | 2019-11-12 |
JP5327816B2 (ja) | 2013-10-30 |
ES2423484T3 (es) | 2013-09-20 |
PL2129373T3 (pl) | 2013-10-31 |
WO2008119544A1 (en) | 2008-10-09 |
KR20100016096A (ko) | 2010-02-12 |
KR101472609B1 (ko) | 2014-12-15 |
US20100120904A1 (en) | 2010-05-13 |
CN101652135B (zh) | 2012-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10471041B2 (en) | Use of geninstein | |
US20120052138A1 (en) | Composition comprising green tea extract | |
US9301943B2 (en) | Use of eupatilin | |
CA3142781A1 (en) | Methods and compositions for altering senescence associated secretory phenotype | |
JP2022525799A (ja) | 骨格筋調節のための新規デプシド二量体化合物、その方法、及びその使用 | |
US20190216707A1 (en) | Composition for preventing hair loss and promoting hair growth, comprising phytoestrogen as an active ingredient | |
US20200261526A1 (en) | Composition For Remedying Female Climacteric Syndrome Symptoms | |
JP5985226B2 (ja) | 過活動膀胱の予防又は改善剤 | |
KR20170055614A (ko) | 토사자 추출물을 또는 그의 분획물을 포함하는 갱년기성 심혈관계 질환의 예방 및 치료용 조성물 | |
JP2021503483A (ja) | Chp(シクロ−ヒスプロ)を含む骨損失疾患の予防、改善または治療用組成物 | |
US11246813B2 (en) | Composition for preventing hair loss or promoting hair development, comprising irone as active ingredient | |
US11904038B2 (en) | Composition for preventing hair loss or promoting hair development, comprising phellandrene as active ingredient | |
EP2709643B1 (en) | Compositions comprising extracts or materials derived from palm oil vegetation liguor for inhibition of vision loss due to macular degeneration | |
KR102068198B1 (ko) | 털이슬 추출물을 함유하는 여성 폐경기 증후군 예방 또는 치료용 조성물 | |
JP6017330B2 (ja) | 過活動膀胱の予防又は改善剤 | |
US10183054B2 (en) | Compositions comprising extracts or materials derived from palm oil vegetation liquor for inhibition of vision loss due to angiogenesis and method of preparation there | |
EP4167978B1 (en) | Use of juniper (juniperus communis) berries extract, deoxypodophyllotoxin and agathadiol, as positive allosteric modulators of cannabinoid type 1 receptor for treating neuropathic pain and inflammatory pain | |
JP7240714B2 (ja) | γヒドロキシ酪酸受容体結合剤 | |
JP2007277187A (ja) | 新規脂肪細胞分化抑制剤 | |
KR101804296B1 (ko) | 식용피 유래 성분을 포함하는 항암용 조성물 | |
KR101586336B1 (ko) | 에스트로피페이트(Estropipate) 또는 이의 약학적으로 허용 가능한 염을 포함하는 근력약화 관련 질환의 예방 또는 치료용 약학적 조성물 | |
WO2019059275A1 (ja) | 骨のリモデリング促進剤 | |
KR20200122934A (ko) | 기억력 증진 또는 학습 능력 향상용 약학적 조성물 및 건강기능식품 | |
JP2019189598A (ja) | アディポネクチン受容体作動薬及びその使用、並びにアディポネクチン受容体作動用食品組成物及びその使用 | |
KR20190099960A (ko) | 적색 파프리카 추출물 또는 캡산틴을 유효성분으로 포함하는 근육 질환 예방, 개선 또는 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110330 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130205 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130507 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130625 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130717 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5327816 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |